Saturday, 20 February 2016 09:44

Anticoagulation news items. Weeks commencing 15th February 2016

The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis

European Heart Journal

Guidelines recommend decisions on oral anticoagulation be made independently of classification into paroxysmal AF (PAF) or non-PAF. This study suggests NPAF may be linked to increased risk of stroke and mortality vs. PAF, thus AF type may need to be considered.

 

Boehringer announces that idarucizumab (Praxbind®) is now available to be used commercially in England, Ireland and Wales

Biospace Inc.

According to Boehringer, the Health Technology Appraisal bodies in these countries agreed that idarucizumab, which specifically reverses anticoagulant effect of dabigatran, is eligible for full reimbursment without the need for a full appraisal.

 

The past and future of haemophilia: diagnosis, treatments, and its complications

The Lancet

In this seminar, the authors provide an overview of the diagnosis of haemophilia and describe the clinical manifestations and treatment (both on-demand and prophylactic). Inhibitor formation as a complication of replacement therapy and its treatment is also discussed.

 

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions

British Journal of Clinical Pharmacology

This retrospective analysis (n=17,701) found that major bleeding events were more common with NSAID use (vs non-use) in both standard of care (SOC) and rivaroxaban groups. NSAID use had no influence on thromboembolic events in either SOC or rivaroxaban groups.

 

Biologics License Application for andexanet alfa to reverse anticoagulant activity of direct and indirect Factor Xa inhibitors accepted for review by FDA

Biospace Inc.

Andexanet alfa is being developing as an antidote for use in patients treated with a direct or indirect Factor Xa inhibitor when reversal of anticoagulation is needed, such as in life-threatening or uncontrolled bleeding or for emergency surgery and urgent procedures.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services